Laura Durbin

Laura Durbin

Auto-generated profile, based on publicly available information

Laura Durbin

Division of Gastroenterology, Lenox Hill Hospital , New York, NY 10025

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2016 in Injury Epidemiology
Verified
Journal Article
Open access
PDF file
LDLaura Durbin
Laura Durbin
RKRebekah J. Kharrazi
Rebekah J. Kharrazi
RGRebecca Graber
Rebecca Graber
TMThelma J. Mielenz
Thelma J. Mielenz
Social support has been shown to be associated with various positive health outcomes among older adults but has not been previously examined in relation to falls, which are a serious health concern among older adults. This study (n = 1000) uses multivariable logistic regression to evaluate the relationship between social contact and perceived availability of social support and falls among older adults. When adjusting for demographic and other covariates neither relationship was significant. This study does not find evidence to suggest that social support could be a prevention measure for falls. Future research on this topic should focus on careful definition and precise measurement of the social support construct.

20 August 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
BMBhavna Murali
Bhavna Murali
LDLaura Durbin
Laura Durbin
SVSapna Vijaykumar
Sapna Vijaykumar
LYLinda Yang
Linda Yang
SLSong Li
Song Li
OCOtávio Clark
Otávio Clark
Purpose: To report the treatment utilization patterns for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer in urban mainland China (CancerMPact®). Methods: The results presented are from an online survey conducted in September 2019 with 45 physicians treating breast cancer patients from 11 cities in mainland China. Results: Surveyed physicians reported that Stage I HR+/HER2(−) breast cancer patients are often treated with surgery alone (42%), whereas the use of surgery in combination with systemic therapy with or without radiotherapy increases in later stages (Stage II 67%, Stage III 77%). Doxorubicin–cyclophosphamide (AC)-based regimens were the most common in both the neoadjuvant and adjuvant settings in HR+/HER2(−) breast cancer patients, across all stages. In metastatic patients, use of surgery and radiotherapy decreases in favor of utilization of systemic therapy alone. Pre- and post-menopausal metastatic patients were frequently treated with hormone therapy or AC-based regimens in first line. Regardless of the first-line therapy administered, capecitabine-based regimens were commonly used in second line. In third line, chemotherapy regimens containing capecitabine or gemcitabine were given to nearly 40% of HR+/HER2(−) breast cancer patients. There were no standard of care regimens established for fourth or greater lines of treatment. In metastatic HR+/HER2(−) breast cancer, physicians reported 50% objective response rates in first-line settings with a progression-free survival of 16 months. Conclusion: HR+/HER2(−) breast cancer patients in urban mainland China were prescribed chemotherapy regimens more frequently than CDK4/6 inhibitors. Treatment practices varied, with physicians reporting the use of multiple modalities and treatment regimens for their patients.

1 January 2020 in Innovation in Aging
Verified
Journal Article
Open access
PDF file
TMThelma J. Mielenz
Thelma J. Mielenz
MTMelissa Tracy
Melissa Tracy
HJHaomiao Jia
Haomiao Jia
LDLaura L Durbin
Laura L Durbin
JAJohn P Allegrante
John P Allegrante
JSJulie A Sorensen
Julie A Sorensen
Extending the Patient-Centered Medical Home (PCMH) model into the community may address the poor linkage between medical clinics and underserved communities. Our first of three objectives was to determine if peer leaders and wellness coaches can be the relationship center of wellness care. We evaluated the Self-management Resource Center Small Group Programs (SMRCSGP), plus wellness coaching, as a booster intervention in older adults with chronic diseases. Second, we evaluated the role of personal health records (PHR) prototype as the linkage between the clinic and community. Using input from these two objectives, we lay the groundwork for the Person-centered Wellness Home (PCWH). Participants enrolled from five South Bronx New York City Housing Authority communities. We conducted a pragmatic, randomized controlled trial using two arms (n = 121): (1) SMRCSGP and (2) SMRCSGP plus wellness coaching initiated as a booster after SMRCSGP completion. Adjusted individual growth models compared the slope differences for outcomes. We conducted a social networking analysis on the ties between wellness coaches and participants. PCMH-certified physicians completed in-depth interviews on the PHR prototype. An adaptation from the consensus-workshop model summarized the priority PCWH items. There was an improvement in self-reported physical functioning (2.0 T-score units higher, p = .03) by the wellness coaching group, but the groups did not differ on physical activity. From the social networking analysis, connections were stable over time with wellness-coaches and participants. The Consensus Conference identified eight major components of the PCWH. Wellness coaching post-SMRCSGP was a booster to physical function, an upstream outcome for physical activity. During the Consensus-Conference, community-based prevention marketing and personal navigators for connecting to a PCMH emerged as novel components. This supports future work in training community health workers as peer leaders to provide evidence-based programs and other PCWH components.

2 May 2024 in Future Oncology
Verified
Journal Article
Open access
LDLaura Durbin
Laura Durbin
BMBhavna Murali
Bhavna Murali
SLSong Li
Song Li
SHStephanie Hawthorne
Stephanie Hawthorne
OCOtávio Clark
Otávio Clark
Aim: To report the treatment patterns of advanced/metastatic non-small-cell lung cancer (NSCLC) in China from a physician survey (CancerMPact®). Materials & methods: A total of 206 Chinese physicia... Plain language summary The most common type of lung cancer is called non-small-cell lung cancer (NSCLC). When lung cancer spreads beyond the lung, it is called advanced. Doctors in China who treat ...

2 August 2023 in Future Oncology
Verified
Journal Article
Open access
XZXinmei Zhu
Xinmei Zhu
LDLaura Durbin
Laura Durbin
GKGena Kanas
Gena Kanas
KPKelesitse Phiri
Kelesitse Phiri
KKKatie Keeven
Katie Keeven
KBKelly F Bell
Kelly F Bell
Aim: To estimate the incidence, prevalence and treated prevalence by line of therapy (LOT) for non-small-cell lung cancer (NSCLC) patients without driver mutations from 2021 to 2026. Materials & me... Plain language summary Lung cancer is the leading cause of cancer-related death in Europe. This study estimated how the number of patients living with, and being treated for, lung cancer is project... Tweetable abstract This RWE-based study projects an increase in incidence, prevalence, and treated prevalence of Stage IIIB/C and Stage IV NSCLC, including difficult-to-treat patients w/o driver mu...

1 October 2021 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
JSJonathan M Schachne
Jonathan M Schachne
LDLaura L Durbin
Laura L Durbin
CLCorey R Lacher
Corey R Lacher
MSMaheep Sangha
Maheep Sangha
AMAnjali Mone
Anjali Mone
ASArun Swaminath
Arun Swaminath
Background: Infliximab is a weight-based prescription for multiple autoimmune diseases and is dispensed only in single-use, 100mg vials. We aim to compute the quantity of infliximab waste at our site and in an ideal world where weight-based prescribing practices are followed. We estimate hypothetical waste reduction and cost-savings if a smaller vial is dispensed. We also surveyed gastroenterologists to study prescription rounding practices for infliximab. Methods: A pre-existing registry of 426 inflammatory bowel disease patients identified 112 individuals who had received a total of 1003 infliximab administrations from December 2013 to May 2019. We calculated infliximab wastage per administration for the real world and an ideal (weight-based) world. Analysis of potential waste reduction and cost-savings was computed with the hypothetical creation of 50 and 25mg vials. Infliximab-prescribing gastroenterologists completed an online survey, determining reasons for rounding of weight-based prescription, rounding practices, and biosimilar use. Results: At our site, the total value of infliximab wasted was between $112738.08 and $243209.50. Utilizing 50 and 25mg vials would reduce this waste by 92.2% and 99.4%, respectively. If prescriber guidelines were followed precisely, the total value of waste was between $132781.08 and $286448.19. Utilizing 50 and 25mg vials would reduce waste by 50.39% and 75.34%, respectively. The physician survey revealed that 68.1% rounded doses while only 31.9% prescribed exact weight-based doses. Conclusions: Infliximab-prescribing gastroenterologists considered reducing drug waste as a common reason in their rounding practices. Our analysis demonstrates significant waste reduction and cost-savings are possible with the introduction of 50 and 25mg vials.